Products & Technology

Overview

We specialise in the discovery of small molecule drug candidates from nature

The products and services we offer range from licensing of individual chemicals from our internal discovery pipeline through to generating a customised small molecule portfolio in a specific therapeutic area.

We have significant flexibility in tailoring our products and discovery technology to the needs of individual clients by:

  • devising new collection strategies for specific therapeutic areas and/or likely modes of action, and
  • searching for particular classes of molecules in our collections and extract libraries.

Our products and services are underpinned by EcoLogic™, our powerful proprietary technology which provides a rational basis for harnessing nature's chemistry in drug discovery.

 

Therapeutic Areas

Our current discovery activities focus on four therapeutic areas for human and animal health;

  • Oncology;
  • Infectious diseases;
  • Inflammation; and,
  • Parasite control.

We are in the process of refining EcoLogic™ to expand its application to discovery in a wider range of therapeutic areas including analgesics, central nervous system and cardiovascular diseases.

 

Discovery Technology

The strength of our business lies in the diverse portfolio of small molecules that we can generate using our proprietary discovery technology EcoLogic™.

EcoLogic™ allows us to access a wealth of new chemical talent in tropical rainforest plants and microbes. Because of the chemical diversity we find, we have the opportunity to cull rigorously early in the discovery process so that the only molecules we move into further development have highly desirable properties as leads for drug development.

Typical properties of small molecules in EcoBiotics portolio:

  • Structural novelty
  • Selectivity of action
  • Strong potency
  • Good stability and solubility properties
  • Good potential for commercial production
  • Strong patent position

EcoLogic™ is a powerful tool which provides a rational basis for drug discovery from nature. Broadly, the technology integrates:

  • specific knowledge of the plants, animals and microbes of tropical rainforest ecosystems and the chemistry that drives their ecological interactions; and,
  • mechanistic understanding of defence chemistry and signal induction and transduction in rainforest plants.

Applying EcoLogic™ gives us a well documented, clearly defined and easily defensible pathway to discovery of our products.

To support our unencumbered ownership of all intellectual property associated with the discovery process using EcoLogic™, we also have benefit sharing agreements with government and private landholders in Queensland and Melanesia. These agreements give our discovery program access to more than 1 million hectares of the world's most diverse rainforests, from humid coastal lowlands to mountain cloud forests.

 

Collections & Libraries

EcoBiotics has over 7,000 collections of biological material, principally plants and higher fungi, targeted using EcoLogic™.

These collections come from a wide variety of rainforest types and are taxonomically very diverse comprising:

  • almost 100 families;
  • more than 250 genera; and,
  • in excess of 3,000 species.

In addition, we have an extensive extract library with more than 5,000 fractions which have activity in one or more of the following preliminary screens: anticancer, anti-inflammatory, antibiotic, antiprotozoal, anthelmintic, antifungal and insecticidal.